Andrin Oswald - Articles and news items


Novartis Holly Springs facility becomes first US pandemic-ready site licensed by the FDA to produce cell-culture influenza vaccines

Industry news / 16 June 2014 / Novartis

Novartis announced that the US Food and Drug Administration licensed its manufacturing facility in Holly Springs, N.C. for the production of cell-culture influenza vaccines…


Novartis provides second US university with Bexsero® to help protect students and staff against potentially deadly meningitis B disease

Industry news / 24 February 2014 / Novartis

Novartis announced that its meningococcal serogroup B vaccine, Bexsero®, will be used as part of a vaccination program at the University of California Santa Barbara and will end on March 7…

Novartis logo

Novartis supplies MenB vaccine, Bexsero®, to Princeton University to help protect students from potentially deadly outbreak

Industry news / 9 December 2013 / Novartis

Novartis supplies MenB vaccine for a vaccination program at Princeton, following approvals by health authorities and University officials…

Novartis logo

Novartis announces positive clinical trial results for novel H7N9 vaccine

Industry news / 14 November 2013 / Novartis

85% of subjects immunologically protected after receiving second dose of investigational cell culture vaccine when combined with proven MF59® adjuvant…

Novartis logo

Novartis vaccine Bexsero® approved in Australia to help protect against MenB disease

Industry news, News / 15 August 2013 / Novartis

The Australian Therapeutic Goods Administration (TGA) has added Bexsero® to the Australian Register of Therapeutic Goods (ARTG)…

Novartis logo
Novartis logo

UK children remain unnecessarily at risk for life-threatening and disabling meningitis B disease

Industry news, News / 24 July 2013 / Novartis

Following JCVI interim recommendation on Novartis Bexsero® vaccine…

Novartis logo

Novartis receives EU approval for Bexsero®

Industry news, News / 22 January 2013 / Novartis

Bexsero®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe…

Novartis logo
Novartis logo
Novartis logo

Novartis receives positive CHMP opinion for Bexsero®

Industry news, News / 16 November 2012 / Novartis

The CHMP of the EMA has adopted a positive opinion for Bexsero for use in individuals from 2 months of age and older…

Novartis logo

Health Canada and Swissmedic lift precautionary holds on Novartis seasonal influenza vaccines

Industry news, News / 31 October 2012 / Novartis

Novartis welcomes the decisions by Health Canada and Swiss Agency for Therapeutic Products, Swissmedic…

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...